MBMichaela Barnikel

Michaela Barnikel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michaela Barnikel has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Nikolaus Kneidinger

    Department of Internal Medicine Division of Respiratory Medicine, Lung Research Cluster Medical University of Graz Graz Austria

    8 shared publications
  • Jürgen Behr

    Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), 81377 Munich, Germany

    6 shared publications
  • Katrin Milger

    Department of Medicine V, LMU University Hospital, LMU Munich , Munich

    6 shared publications
  • Carlo Mümmler

    Department of Medicine V LMU University Hospital, LMU Munich, Comprehensive Pneumology Center (CPC), Member of the German Center of Lung Research (DZL) Munich Germany

    3 shared publications
  • Gabriela Leuschner

    Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), 81377 Munich, Germany

    3 shared publications
  • Paola Arnold

    Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center (CPC-M), Member of the German Center for Lung Research (DZL), 81377 Munich, Germany

    3 shared publications

Latest Publications

  • Open Access

    Obstructive Ventilatory Defects in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

    by Torben Sonneck, Michaela Barnikel, Paola Arnold, Gabriela Leuschner, Amanda Tufman, Jürgen Behr

    Background/Objectives: Patients with pulmonary arterial hypertension (PAH) may display obstructive ventilatory defects outside of defined obstructive lung disease. However, its pathogenesis and prognostic relevance remain unknown. Similar data have emerged for patients with chronic thromboembolic pulmonary hypertension (CTEPH), but there is no description in a real-world European cohort. Methods: We performed a single-center, retrospective, cross-sectional study of patients with PAH (n = 46) and CTEPH (n = 45) at an academic PH center. Data were collected on pulmonary function tests, DLCO, right heart catheterization results, pre-existing diagnoses of asthma and chronic obstructive pulmonary disease (COPD), current medications, and adverse outcomes. Results: Patients with PAH and CTEPH showed a reduced FVC (81% for both groups), FEV1 (74 and 75%) and DLCO (54 and 53%). A previous diagnosis of COPD was documented in 11% of patients, and asthma in 11% of patients with PAH and 4.5% of patients with CTEPH respectively. Even after excluding patients with asthma or COPD, ventilatory obstruction was still present in at least 22% of patients and 16% were being treated with long-acting bronchodilators or inhaled corticosteroids. Of these patients, those who had adverse outcomes (active listing for lung transplantation, lung transplantation or death) had a significantly lower FVC (68 vs. 83%, p = 0.026), FEV1 (61 vs. 79%, p = 0.01) and MEF50 (38 vs. 59%, p = 0.021). All patients with adverse outcomes had a mean expiratory flow at 50% vital capacity (MEF50) < 60%, as opposed to 57% of those without an adverse event, however MEF50 did not predict adverse outcomes after adjusting for FVC. Conclusions: Ventilatory obstruction is common in patients with PAH and CTEPH even when excluding patients with asthma/COPD or a history of smoking. Symptomatic treatment with bronchodilators is common even without these comorbidities. Patients with adverse outcomes had lower FEV1, FVC and MEF50, but the functional relevance of the latter remains to be explored.

  • Open Access

    Classification and course of pulmonary hypertension associated with end-stage COPD

    by Michaela Barnikel, Katrin Milger, Pontus Mertsch, Paola Arnold, Gabriela Leuschner, Tobias Veit, Michael Gerckens, Carlo Mümmler, Jürgen Barton, Alessandro Ghiani, et al.

    Background: Pulmonary hypertension (PH) associated with COPD contributes to morbidity and mortality. Further characterisation to improve management is warranted. The aim of the study was to apply the recently proposed PH classification and to assess the association of lung volume involvement and PH over the course of disease in patients with advanced COPD. Methods: Patients with COPD undergoing transplant evaluation, including right heart catheterisation were included irrespective of the likelihood of having PH. Spirometry, plethysmography and computed tomography were used to assess the degree of parenchymal and vascular involvement. Follow-up investigation was performed for 18±12 months. The 2022 European Society of Cardiology/European Respiratory Society guidelines were used for classification of PH. Results: In total, 340 patients were included and 639 right heart catheters were assessed. The majority of patients were classified as no PH (n=131, 38%) or nonsevere PH (n=133, 39%), whereas severe COPD-PH was present in 26 patients (8%). Patients with severe COPD-PH had similar degrees of airflow obstruction but lower lung volumes. Further, pulmonary vascular resistance (PVR) correlated negatively with residual volume. Interstitial lung abnormalities were present in 11 patients (3%) and scattered across all PH groups. Follow-up (n=141, 41.5%) demonstrated a low rate of deterioration to severe COPD-PH (4%). However, an increase of PVR was common and was associated with a decrease of total lung capacity. Conclusion: Unbiased longitudinal invasive follow-up and assessment of lung volumes by plethysmography provided evidence of an association of lung volume and PVR.


  • Open Access

    Current Blood Eosinophilia Does Not Predict the Presence of Pulmonary Hypertension in Patients with End-Stage Lung Disease

    by Michaela Barnikel, Nikolaus Kneidinger, Michael Gerckens, Carlo Mümmler, Alexandra Lenoir, Pontus Mertsch, Tobias Veit, Gabriela Leuschner, Andrea Waelde, Claus Neurohr, et al.

    Objectives: To investigate the role of blood eosinophils in predicting PH in end-stage lung disease. Methods: We conducted a retrospective study of adults with CF, COPD, and ILD who underwent RHC during lung transplant evaluations (2010–2022). Patients were classified by the 2022 ECS/ERS PH guidelines with pulmonary function and laboratory tests, including hemograms. The eosinophil threshold was set at 0.30 G/L. Results: We analyzed 663 patients (n = 89 CF, n = 294 COPD, and n = 280 ILD). Severe PH was more common in ILD (16%) than in CF (4%) and COPD (7%) (p = 0.0002), with higher eosinophil levels in ILD (p = 0.0002). No significant correlation was found between eosinophil levels and hemodynamic parameters (PAPm, PVR, and CI) across CF, COPD, and ILD (PAPm: p = 0.3974, p = 0.4400 and p = 0.2757, respectively; PVR: p = 0.6966, p = 0.1489 and p = 0.1630, respectively; CI: p = 0.9474, p = 0.5705 and p = 0.5945, respectively), nor was a correlation observed in patients not receiving OCS. Linear regression analysis confirmed the lack of association (PAPm: p = 0.3355, p = 0.8552 and p = 0.4146, respectively; PVR: p = 0.6924, p = 0.8935 and p = 0.5459, respectively; CI: p = 0.4260, p = 0.9289 and p = 0.5364, respectively), controlling for 6-MWD, Nt-proBNP, and ICS/OCS dosages. ROC analysis indicated eosinophils were ineffective in distinguishing PH severity levels across these diseases (AUC 0.54, 0.51, and 0.53, respectively). The analysis of eosinophil levels measured 18 ± 6 months prior to baseline found no predictive correlation with the presence of PH either. Eosinophil levels did not differ significantly among PH groups, but eosinophilic COPD was linked to more unclassified PH, higher CO, and greater lung volumes than non-eosinophilic COPD. Conclusions: In our cohort of end-stage CF, COPD, and ILD patients, blood eosinophilia did not predict the presence of PH but was associated with hemodynamic parameters and lung volumes in COPD.


  • Open Access

    Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis

    by Carlo Mümmler, Pontus Mertsch, Michaela Barnikel, Frank Haubner, Ulf Schönermarck, Ulrich Grabmaier, Hendrik Schulze-Koops, Jürgen Behr, Nikolaus Kneidinger, Katrin Milger

    Background: Benralizumab reduces exacerbations and long-term oral glucocorticosteroid (OCS) exposure in patients with severe eosinophilic asthma. In patients with eosinophilic granulomatosis with polyangiitis (EGPA), uncontrolled symptoms and exacerbations of asthma and chronic rhinosinusitis (CRS) are important reasons for continued OCS therapies. We aimed to describe outcomes of patients with severe asthma and EGPA treated with benralizumab in real-life. Methods: We retrospectively analyzed adult patients from the Severe Asthma Unit at LMU Munich diagnosed with severe asthma and EGPA treated with benralizumab, differentiating two groups: Group A, patients with a stable daily OCS dose and diagnosis of EGPA > 6 months ago; and Group B, patients treated with high-dose daily OCS due to recent diagnosis of EGPA < 6 months ago. We compared outcome parameters at baseline and 12 months after initiation of benralizumab, including respiratory exacerbations, daily OCS dose, and lung function. Results: Group A included 17 patients, all receiving OCS therapy and additional immunosuppressants; 15 patients (88%) continued benralizumab for more than 12 months, demonstrating a significant reduction in daily OCS dose and exacerbations while FEV1 increased. Group B included 9 patients, all with high-dose daily OCS and some receiving cyclophosphamide pulse therapy for life-threatening disease. Benralizumab addition during induction was well tolerated. A total of 7/9 (78%) continued benralizumab for more than 12 months and preserved EGPA remission at the 12-month timepoint. Conclusion: In this real-life cohort of patients with severe asthma and EGPA, benralizumab initiation during remission maintenance reduced respiratory exacerbations and daily OCS dose. Benralizumab initiation during remission induction was associated with a high rate of clinical EGPA remission.


  • Open Access

    Domestic Parasitic Infections in Patients with Asthma and Eosinophilia in Germany – Three Cases with Learnings in the Era of Anti- IL5 Treatments

    by Michaela Barnikel, Ulrich Grabmaier, Pontus Mertsch, Felix Ceelen, Christian Janke, Jürgen Behr, Nikolaus Kneidinger, Katrin Milger

    Eosinophilic inflammation is a hallmark of asthma, and blood eosinophilia has been established as a biomarker for phenotyping asthma and predicting the response to anti-IL5 treatments. Although parasitic infections are rare in European adults, they remain an important differential diagnosis for blood eosinophilia. We present three patients with both domestic parasitic infections and asthma to raise awareness of the potential challenge of eosinophilia and to provide experience in the management of parasitic infections in the setting of planned or ongoing anti-IL5 treatment. One, a patient from Croatia with moderate asthma but severe blood eosinophilia had an underlying Strongyloides stercoralis infection, with positive stool cultures. Second, a patient with severe allergic asthma and gastrointestinal symptoms had a positive S. stercoralis titer in serology with a clinical response to treatment with ivermectin. Third, a patient with severe nonallergic eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA) showed an increasing hepatic tumour under anti-IL5-receptor therapy. Positive serology confirmed the diagnosis of Echinococcus multilocularis, and albendazole therapy was initiated. Anti-IL5 therapies were safely started (Patient 2) or resumed (Patient 3) after the initiation of antiparasitic treatment. Screening for parasitic infections is useful in cases of hypereosinophilia, extrapulmonary symptoms or stay in endemic regions.


  • Open Access

    Clinical Impact of Physical Activity and Cough on Disease Progression in Fibrotic Interstitial Lung Disease

    by Tobias Veit, Michaela Barnikel, Nikolaus Kneidinger, Dieter Munker, Paola Arnold, Jürgen Barton, Alexander Crispin, Katrin Milger, Jürgen Behr, Claus Neurohr, et al.

    Physical activity limitations and cough are common in patients with interstitial lung disease (ILD), potentially leading to reduced health-related quality of life. We aimed to compare physical activity and cough between patients with subjective, progressive idiopathic pulmonary fibrosis (IPF) and fibrotic non-IPF ILD. In this prospective observational study, wrist accelerometers were worn for seven consecutive days to track steps per day (SPD). Cough was evaluated using a visual analog scale (VAScough) at baseline and weekly for six months. We included 35 patients (IPF: n = 13; non-IPF: n = 22; mean ± SD age 61.8 ± 10.8 years; FVC 65.3 ± 21.7% predicted). Baseline mean ± SD SPD was 5008 ± 4234, with no differences between IPF and non-IPF ILD. At baseline, cough was reported by 94.3% patients (mean ± SD VAScough 3.3 ± 2.6). Compared to non-IPF ILD, patients with IPF had significantly higher burden of cough (p = 0.020), and experienced a greater increase in cough over six months (p = 0.009). Patients who died or underwent lung transplantation (n = 5), had significantly lower SPD (p = 0.007) and higher VAScough (p = 0.047). Long-term follow up identified VAScough (HR: 1.387; 95%-CI 1.081–1.781; p = 0.010) and SPD (per 1000 SPD: HR 0.606; 95%-CI: 0.412–0.892; p = 0.011) as significant predictors for transplant-free survival. In conclusion, although activity didn’t differ between IPF and non-IPF ILD, cough burden was significantly greater in IPF. SPD and VAScough differed significantly in patients who subsequently experienced disease progression and were associated with long-term transplant-free survival, calling for better acknowledgement of both parameters in disease management.


  • Parasitosen bei Patienten mit eosinophilem Asthma – 3 Fälle

    by M Barnikel, P Mertsch, F Ceelen, J Behr, N Kneidinger, K Milger-Kneidinger

    Hintergrund Parasitosen sind eine klassische Ursache einer Eosinophilie, jedoch sind diese bei Erwachsenen in Deutschland ohne Reiseanamnese relativ selten. Das Asthma dagegen stellt eine häufige Ursache einer Eosinophilie dar. Fallserie Wir beschreiben 3 Fälle einheimisch erworbener Parasitosen aus unserer Ambulanz für schweres Asthma: Schlussfolgerung Parasitosen sind eine relevante Differenzialdiagnose, die auch bei Patienten mit gesichertem Asthma in Betracht gezogen werden muss. Bei atypischen Symptomen sollte eine Parasitendiagnostik erfolgen, insbesondere vor Beginn von systemischen Asthma-Therapien. Article published online: 09 March 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany

  • Open Access

    Follow-up lung ultrasound to monitor lung failure in COVID-19 ICU patients

    by Michaela Barnikel, Annabel Helga Sophie Alig, Sofia Anton, Lukas Arenz, Henriette Bendz, Alessia Fraccaroli, Jeremias Götschke, Marlies Vornhülz, Philipp Plohmann, Tobias Weiglein, et al.

    Objectives: Point-of-care lung ultrasound (LU) is an established tool in the first assessment of patients with coronavirus disease (COVID-19). To assess the progression or regression of respiratory failure in critically ill patients with COVID-19 on Intensive Care Unit (ICU) by using LU. Materials and methods: We analyzed all patients admitted to Internal Intensive Care Unit, Ludwig-Maximilians-University (LMU) of Munich, from March 2020 to December 2020 suffering lung failure caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). LU was performed according to a standardized protocol at baseline and at follow up every other day for the first 15 days using a lung ultrasound score (LUSS). Ventilation data were collected simultaneously. Results: Our study included 42 patients. At admission to ICU, 19 of them (45%) were mechanically ventilated. Of the non-invasive ventilated ones (n = 23, 55%), eleven patients required invasive ventilation over the course. While LUS did not differ at admission to ICU between the invasive ventilated ones (at baseline or during ICU stay) compared to the non-invasive ventilated ones (12±4 vs 11±2 points, p = 0.2497), LUS was significantly lower at d7 for those, who had no need for invasive ventilation over the course (13±5 vs 7±4 points, p = 0.0046). Median time of invasive ventilation counted 18 days; the 90-day mortality was 24% (n = 10) in our cohort. In case of increasing LUS between day 1 (d1) and day 7 (d7), 92% (n = 12/13) required invasive ventilation, while it was 57% (n = 10/17) in case of decreasing LUS. At d7 we found significant correlation between LU and FiO2 (Pearson 0.591; p = 0.033), p/F ratio (Pearson -0.723; p = 0.005), PEEP (Pearson 0.495; p = 0.043), pplat (Pearson 0.617; p = 0.008) and compliance (Pearson -0.572; p = 0.016). Conclusion: LUS can be a useful tool in monitoring of progression and regression of respiratory failure and in indicating intubation in patients with COVID-19 in the ICU.


  • Open Access

    The Feasibility of Percutaneous Dilatational Tracheostomy in Immunosuppressed ICU Patients with or without Thrombocytopenia

    by Marianne Angelberger, Michaela Barnikel, Alessia Fraccaroli, Johanna Tischer, Sofía Antón, Alexandra Pawlikowski, Mark Op Den Winkel, Hans Joachim Stemmler, Stephanie-Susanne Stecher

    Background. Percutaneous dilatational tracheostomy (PDT) has become the preferred method in several intensive care units (ICUs), but data on PDT performed in immunosuppressed and thrombocytopenic patients are scarce. This study aimed to analyze the feasibility of PDT in immunosuppressed and thrombocytopenic patients compared to conventional open surgical tracheostomy (OST). Methods. We retrospectively analyzed the charts of patients who underwent PDT or OST between May 2017 and November 2020. Our outcomes were stoma site infections and bleeding complications. Results. 63 patients underwent PDT, and 21 patients underwent OST. Distribution of gender ratio, age, SAPS II, time of ventilation before tracheostomy, and preexisting hematooncological diseases was comparable between the two groups. After allogeneic stem cell transplantation (alloSCT), patients were more likely to undergo PDT than OST ( ). The PDT cohort suffered from mucositis more frequently ( ). There were no significant differences in leucocyte or platelet count on the tracheostomy day. Patients with coagulation disorders and patients under immunosuppression were distributed equally among both groups. Stoma site infection was documented in five cases in PDT and eight cases in the OST group. Moderate infections were remarkably increased in the OST group. Smears were positive in six cases in the PDT group; none of these patients had local infection signs. In the OST group, smears were positive in four cases; all had signs of a stroma site infection. Postprocedural bleedings occurred in eight cases (9.5%) and were observed significantly more often in the OST group ( ), leading to emergency surgery in one case of the OST group. Conclusion. PDT is a feasible and safe procedure in a predominantly immunosuppressed and thrombocytopenic patient cohort without an increased risk for stoma site infections or bleeding complications.


  • Open Access

    Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities

    by Michaela Barnikel, Nikolaus Kneidinger, Paola Arnold, Andrea Waelde, Jürgen Behr, Katrin Milger

    Riociguat is licensed for the therapy of inoperable chronic thromboembolic pulmonary hypertension (CTEPH). We aimed to investigate whether age and comorbidities influence its tolerability and efficacy. Retrospectively, we analyzed data of tolerability, non-invasive, and invasive efficacy at baseline and follow up (FU) of all patients with CTEPH treated with riociguat at the Department of Internal Medicine V, University of Munich (n = 47), grouping patients according to age (<65 versus 65–79 versus ≥80 years) and risk factors for heart failure with preserved ejection fraction (HFpEF) (80 years reported side effects more frequently (40%) than the other age groups (23% and 21% for patients <65 years and patients 65–79, respectively). Cessation of riociguat was rare and occurred independent of age. When looking at the total cohort of 47 patients, three patients stopped therapy and three patients had a reduced maintenance dosage, while 41/47 (87%) and all octogenarians reached the highest maintenance dosage of 7.5 mg/d. The frequency of any side effect was similar in patients in both risk factor groups, and hypotension was only observed in those with <2 risk factors. Parameters of efficacy improved significantly under riociguat treatment. Improvement in 6-min walk distance (6 mwd), N-terminal pro brain natriuretic peptide (Nt-proBNP) and hemodynamics did not differ between age or risk factor groups. In this small real-life cohort, riociguat was well-tolerated and effective in advanced age and risk factors for HFpEF.